{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:01:22Z","timestamp":1794283282561,"version":"4.9.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate whether the increased risk of breast cancer is dependent on the formulation of menopausal hormone therapy (HT) used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We performed a population-based case\u2013control study of women aged 50 years or older using data from the U.K. Clinical Practice Research Datalink. Women with incident cases of breast cancer were age-matched (1:10) with a control group of women with comparable follow-up time with no history of breast cancer. Exposures were classified as ever or never for the following menopausal HT formulations: bioidentical estrogens, animal-derived estrogens, micronized progesterone, and synthetic progestin. Logistic regression analyses were performed to estimate the adjusted effect of menopausal HT formulation on breast cancer risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Between 1995 and 2014, 43,183 cases of breast cancer were identified and matched to 431,830 women in a control group. In adjusted analyses, compared with women who never used menopausal HT, its use was associated with an increased risk of breast cancer (odds ratio [OR] 1.12, 95% CI 1.09\u20131.15). Compared with never users, estrogens were not associated with breast cancer (bioidentical estrogens: OR 1.04, 95% CI 1.00\u20131.09; animal-derived estrogens: OR 1.01, 95% CI 0.96\u20131.06; both: OR 0.96, 95% CI 0.89\u20131.03). Progestogens appeared to be differentially associated with breast cancer (micronized progesterone: OR 0.99, 95% CI 0.55\u20131.79; synthetic progestin: OR 1.28, 95% CI 1.22\u20131.35; both OR 1.31, 0.30\u20135.73).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Although menopausal HT use appears to be associated with an overall increased risk of breast cancer, this risk appears predominantly mediated through formulations containing synthetic progestins. When prescribing menopausal HT, micronized progesterone may be the safer progestogen to be used.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000004723","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T07:00:30Z","timestamp":1654153230000},"page":"1103-1110","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":56,"title":["Menopausal Hormone Therapy Formulation and Breast Cancer Risk"],"prefix":"10.1097","volume":"139","author":[{"given":"Haim A.","family":"Abenhaim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Spence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Czuzoj-Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Togas","family":"Tulandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM199109123251102","article-title":"Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study","volume":"325","author":"Stampfer","year":"1991","journal-title":"N Engl J Med"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","article-title":"Effects of estrogen or estrogen\/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial","volume":"273","year":"1995","journal-title":"JAMA"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the million women study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1471-0528.2007.01520.x","article-title":"Hormone replacement therapy use and variations in the risk of breast cancer","volume":"115","author":"Opatrny","year":"2008","journal-title":"BJOG"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int J Cancer"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09513590.2016.1248932","article-title":"Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis","volume":"33","author":"Yang","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"R11-20250423","first-page":"24","article-title":"In Defense of progesterone: a review of the literature","volume":"23","author":"Lieberman","year":"2017","journal-title":"Altern Ther Health Med"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13643-016-0294-5","article-title":"Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis","volume":"5","author":"Asi","year":"2016","journal-title":"Syst Rev"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","article-title":"All progestins are not created equal","volume":"68","author":"Stanczyk","year":"2003","journal-title":"Steroids"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2125.1998.00701.x","article-title":"Use of the UK general practice research database for pharmacoepidemiology","volume":"45","author":"Garc\u00eda Rodr\u00edguez","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.302.6779.766","article-title":"Validation of information recorded on general practitioner based computerised data resource in the United Kingdom","volume":"302","author":"Jick","year":"1991","journal-title":"BMJ"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1592\/phco.23.5.686.32205","article-title":"Validity of the general practice research database","volume":"23","author":"Jick","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2125.2000.00199.x","article-title":"Validation of the diagnosis of venous thromboembolism in general practice database studies","volume":"49","author":"Lawrenson","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/pubmed\/21.3.299","article-title":"Clinical information for research; the use of general practice databases","volume":"21","author":"Lawrenson","year":"1999","journal-title":"J Public Health Med"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"Management of menopausal symptoms","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/gme.0b013e31812f7b65","article-title":"Risk perception in women: a focus on menopause","volume":"15","author":"Deeks","year":"2008","journal-title":"Menopause"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/03630240903158446","article-title":"Physicians' and women's views on hormone therapy and breast cancer risk after the WHI: a qualitative study","volume":"49","author":"Nekhlyudov","year":"2009","journal-title":"Women Health"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1210\/en.2007-1612","article-title":"Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate","volume":"149","author":"Otto","year":"2008","journal-title":"Endocrinology"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10549-006-9276-y","article-title":"Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys","volume":"101","author":"Wood","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/jamaoncol.2015.0494","article-title":"Breast cancer after Use of estrogen plus progestin and estrogen Alone: analyses of data from 2 Women's Health Initiative randomized clinical trials","volume":"1","author":"Chlebowski","year":"2015","journal-title":"JAMA Oncol"},{"key":"R26-20250423","doi-asserted-by":"crossref","first-page":"e78016","DOI":"10.1371\/journal.pone.0078016","article-title":"Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France","volume":"8","author":"Cordina-Duverger","year":"2013","journal-title":"PLoS One"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2017.07.012","article-title":"Menopausal hormone therapy and cancer risk: an overestimated risk?","volume":"84","author":"Simin","year":"2017","journal-title":"Eur J Cancer"},{"key":"R28-20250423","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13697137.2017.1421925","article-title":"The impact of micronized progesterone on breast cancer risk: a systematic review","volume":"21","author":"Stute","year":"2018","journal-title":"Climacteric"},{"key":"R29-20250423","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1055-9965.EPI-12-0043","article-title":"Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy","volume":"21","author":"Santen","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R30-20250423","doi-asserted-by":"crossref","first-page":"564781","DOI":"10.3389\/fendo.2021.564781","article-title":"Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:02:55Z","timestamp":1745420575000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004723","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"2021-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}